LONDON, England — A brain-computer interface developed by Neuralink Corp. has enabled a quadriplegic participant to control digital devices with thought alone in the company’s early feasibility trial, according to clinical records and participant accounts.
The GB-PRIME study is a prospective trial of Neuralink’s investigational N1 brain implant and R1 robotic surgical system, designed to assess the safety and basic functionality of the technology for adults with tetraplegia or comparable paralysis.
The trial is sponsored by Neuralink and involves participants who cannot use their hands to operate computers, tablets or other external devices.
Researchers and regulators approved the study in Great Britain in mid-2025.
The Medicines and Healthcare products Regulatory Agency, Health Research Authority, Health and Care Research Wales and a research ethics committee authorized implantation at University College London Hospitals and Newcastle upon Tyne hospitals.
Early UK Results
In late 2025, a participant in the GB-PRIME study at University College London Hospitals used the implant to move a computer cursor using thought alone within hours of surgery, clinical researchers reported.
The patient, who has motor neurone disease and significant paralysis, left the hospital the day after the procedure.
In January 2026, another UK volunteer, identified as Sebastian Gomez-Pena, who is quadriplegic, said the implant gave him the ability to navigate his laptop without moving his hands.
Gomez-Pena described the experience as offering “a new piece of hope,” and said he could control the cursor and click on content by thinking about hand movement.
A surgeon leading the UK procedures said the performance of the interface showed promising control signals from the motor cortex.
Gomez-Pena is one of several participants in Great Britain taking part in this multi-site feasibility study.
Trial Design and Participants
According to the Health Research Authority, GB-PRIME plans to enroll up to seven participants with tetraparesis or tetraplegia caused by spinal cord injury, motor neurone disease such as ALS, stroke or other neurological conditions.
The study will track device safety, neural signal decoding ability, and functional outcomes such as computer control.
Researchers will follow participants over several years to monitor long-term safety and signal stability.
The implant uses more than 1,000 tiny electrode threads inserted into the motor cortex to capture and wirelessly transmit neural signals to external computers, according to the clinical trial record.
Context from U.S. Trials
The GB-PRIME study builds on Neuralink’s ongoing PRIME trial in the United States, where multiple quadriplegic participants have used the implant to operate computers and other digital tools directly via neural activity.
One of the first U.S. recipients, Noland Arbaugh, a quadriplegic man injured in a spinal accident, was able to control a computer cursor and play games using only thought signals from his Neuralink implant.
Updates from the PRIME trial reported that subsequent participants quickly achieved high levels of cursor control, surpassing prior benchmarks for brain-computer interface performance.
What Comes Next
GB-PRIME will continue enrolling and monitoring participants through early 2031, with interim safety and feasibility reports expected at regular intervals as specified on the ClinicalTrials.gov registry.
If long-term safety and functional gains are confirmed, Neuralink expects to expand the technology’s applications to broader clinical use and to support regulatory review in additional markets.
